A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.

Study Overview

• Status: Recruiting
• Conditions: Recurrent Glioblastoma Multiforme(GBM)
• Intervention / Treatment: Drug: ACT001; Drug: ACT001 + Pembrolizumab

Detailed Description

Phase 1b: The identified RP2D of combined ACT001 with Pembrolizumab will be determined by standard 3+3 dose escalation methodology among three ACT001 dosages (200mg, 400mg and 800mg, BID) with standard Pembrolizumab dosage. Patients will be dosed approximately 2 weeks prior to surgical resection with a single dose of Pembrolizumab and ACT001. Tumor resection will be performed and a biopsy will be obtained from the resected tumor tissue to evaluate the impact of the study drugs on the TME. After recovery from surgery, patients will resume ACT001 and Pembrolizumab until tumor progression (assessed by iRANO) or an AE requiring discontinuation of study drug. The Safety Monitoring Committee (SMC) will review the data available from all evaluable patients at each dose level prior to recommending escalation to the next dose level.

Phase 2a: Using the same dosing schedule and ACT001 dosage as determined in Phase 1b. Patients will be randomized to receive either Pembrolizumab only treatment (Arm A, 10 patients) or ACT001 plus Pembrolizumab treatment (Arm B, 20 patients).

• Study Type: Interventional
• Enrollment (Anticipated): 48
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: C3 Research Associates; Phone Number: 1207 +1 206 686 4644; Email: ACT001-US-001@c3-research.com

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • UT MD Anderson Cancer Center, Dept of Neuro-Oncology
      • Contact: Shiao-Pei Weathers, MD; Phone Number: (713)792-3906; Email: SWeathers@mdanderson.org
      • Contact: Vanessa Santiago, Sr Research Nurse; Phone Number: (713) 563-1603; Email: vsantiago@mdanderson.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patient has provided written informed consent.
2. ≥ 18 years old at time of screening visit.
3. Histologically confirmed GBM at the time of diagnosis.
4. First or second relapse by the time of consenting.
5. Tumor progression (magnetic resonance imaging [MRI], defined by RANO) post prior treatments.
6. Feasibility for re-surgery.
7. Karnofsky Performance Status ≥ 70% (requires occasional assistance, but able to care for most of their needs, equivalent to < ECOG 2).
8. Must be ≥ 4 weeks from administration of last dose of cancer therapy (including radiation therapy or chemotherapy). The patient must have recovered from all treatment-related toxicities to less than grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
9. Life expectancy of ≥ 3 months.
10. Adequate organ function (absolute neutrophil count ≥1.5 x 109 /L, lymphocytes ≥ 0.5 x 109 /L, platelets ≥ 75 x 109 /L, hemoglobin ≥ 10 g/dl; total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5.0 x ULN if liver metastasis); plasma creatinine ≤ 1.5 x ULN; QTc < 450 ms (male), < 470 ms (female).

11. Female patients are eligible if they are of:

    1. Non-childbearing potential, defined as

       • Previous hysterectomy or bilateral oophorectomy
       • Previous bilateral tubal ligation
       • Post-menopausal (total cessation of menses for ≥ 1 year)

    2. Childbearing potential with a negative serum pregnancy test at screening (within 7 days of the first investigational product administration) and uses a highly effective method contraception before study entry and throughout the study until 28 days after the last investigational product administration. Highly effective contraception (<1% failure rate per year), when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:

       • Vasectomized partner who is sterile prior to the female patient's enrolment and is her sole sexual partner
       • An intrauterine device with a documented failure rate of less than 1% per year
       • Double barrier contraception defined as condom with a female diaphragm
12. Male patients, if sexually active, must agree to use a highly effective method of contraception (< 1% failure rate per year) with their female partners from screening until 28 days following the last study drug administration.
13. Absence of deteriorating neurological symptoms, new onset of seizures and the need for increasing doses of corticosteroids.
14. Absence of toxicity from prior therapy (excluding alopecia) that has not resolved to ≤ Grade 1 unless otherwise specified.
15. Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement

Exclusion Criteria:

1. The patient has uncontrolled infection.
2. The patient has serious diseases such as unstable angina pectoris, myocardial infarction in the past 6 months, heart failure (New York Heart Association class > II) or stroke within 6 months prior to the enrollment.
3. A gastrointestinal absorption disorder that would limit the bioavailability of oral drugs or if patient cannot take oral drugs.
4. Uncontrolled brain metastases or spinal cord compression. Patients who were treated with surgical resection or radiation therapy completing at least 4 weeks earlier are eligible if they are neurologically stable, not taking glucocorticoids and have a follow-up. MRI scan performed within the previous 4 weeks showing no tumor progression.
5. Pre-existing allergy to ACT001 or related compounds.
6. A patient has active autoimmune disease managed by systemic treatments in the past 2 years (i.e. the use of corticosteroids, immunosuppressive drugs or other disease modifying agents). Of note, a replacement therapy, e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic treatment.
7. A known history of, or any evidence of an active non-infectious pneumonitis.
8. Treatment with cancer therapies such as chemotherapy or radiation therapy either currently or within 4 weeks of ACT001 dosing. An exception is focal radiation for symptomatic bone metastases, which must not be within 2 weeks of ACT001 dosing.
9. History of treatment with immune CPB and Avastin (or other antiangiogenic or anti-vascular endothelial growth factor agents).
10. High dose of corticosteroids (> 4mg/day of dexamethasone or equivalent for at least 3 consecutive days) within two weeks of enrolment for GBM treatment.
11. A patient has received other systemic immunosuppressive treatments such as mTOR inhibitor everolimus four weeks prior to registration.
12. A patient has a diagnosis of ongoing immunodeficiency due to other diseases such as human immunodeficiency virus (HIV) infection.
13. Unresolved toxicity from prior antitumor therapy, defined as toxicities (excluding alopecia) that have not resolved to < Grade 2 as scored using the CTCAE current version. Exceptions may be allowed for stable toxicities after discussion with the investigator and sponsor.
14. Major surgery within 30 days of commencing first study therapy.
15. Pregnant or breast-feeding females.
16. A history of infection with HIV or hepatitis B or C viruses.
17. The patient has participated in other drug clinical studies < 4 weeks prior to obtaining the informed consent.
18. The patient is, in the opinion of the investigator, unsuitable for any other reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 1b dose exploration; 1b dose exploration for 18 patients - The starting dose of ACT001 will be administered in combination with a single intravenous (IV) infusion of Pembrolizumab. After recovery from surgical resection, dosing will resume on a 3 weekly cycle and will consist of Pembrolizumab (standard dosing) and daily ACT001. Evaluation of a dose level of at least three (3) patients after completing one cycle of treatment post-surgery is required prior to commencing the next dose level.	Drug: ACT001; Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
EXPERIMENTAL: 2a- Randomized/Two-treatment Arm; 30 Patients will be randomized to Arm A or Arm B at a ratio of 1 (Arm A) : 2 (Arm B). 10 patients will be randomized to the Pembrolizumab only arm (Arm A) and 20 patients will be randomized to the ACT001 plus Pembrolizumab arm (Arm B).	Drug: ACT001 + Pembrolizumab; Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1b-Incidence, type and severity of treatment-emergent AEs (TEAEs)		Approximately 7 months. Each cycle is 21 days; from start of first dose with investigational product until completion of the last study related procedure (including follow-up for safety assessments- 30days after last dose)
1b-Dose limiting toxicities (DLTs)	A DLT is defined as any of the following; Haematological toxicityGrade 4 neutropeniaGrade ≥ 3 febrile neutropenia or neutropenic infectionGrade 4 thrombocytopeniaGrade 3 thrombocytopenia with clinically significant bleeding; Non-haematological toxicityGrade ≥ 3 nausea, vomiting or diarrhoea despite optimal supportive therapyGrade ≥ 3 hypertension despite appropriate interventionOther grade ≥ 3 non-haematological toxicity, except grade 3 fatigue or transient events (such as allergic reactions or electrolyte disturbances) that are readily controlled with medical therapy and/or are of no clinical concern	From first dose of study therapy until the end of the first post-surgery cycle (Cycle 1, Day 21).
1b-Mean changes in vital sign measurements-Heart Rate	Mean change from baseline in vital sign measurements reported in beats/min (inclusive) at each study timepoint.	Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
1b-Mean changes in vital sign measurements- supine blood pressure	Mean change from baseline in vital sign measurements reported in mmHg at each study timepoint	Approximately 8months/ patient.Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
1b-Mean changes in vital sign measurements- body temperature	Mean change from baseline in vital sign measurements reported in degrees Celsius (0C) at each study timepoint.	Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
1b-Mean changes in vital sign measurements- respiratory rate	Mean change from baseline in vital sign measurements reported in bpm at each study timepoint	Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
1b-Mean changes in electrocardiogram (ECG) parameters	Mean change from baseline in electrocardiogram (ECG) parameters of heart rate, ventricular rate, PR interval, QRS duration, and QTcF.	approximately 8months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
1b-Mean changes in Karnofsky Performance Scale score	Mean change from baseline in Karnofsky Performance Scale score	Approximately 8 months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
2a-Progression free survival (PFS) at 6 months		Six months after initiation of study therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1b-Incidence of DLTs according to the MTD/RP2D evaluation process.		From first dose of study therapy (per surgery) until the end of the first post-surgery cycle (Cycle 1, Day 21). Each cycle is 21 days.
1b- Pharmacokinetics (PK) of ACT001 in Plasma concentrations in tumor.	Determine ACT001 trough levels in tumor samples.	PK analysis will be collected on Day 1 of the pre surgical treatment period.
2a-Overall survival	Overall survival (OS) is defined as time from start of ACT001 dosing at day 1 of cycle 1 until the date of death or date from any cause, assessed up to disease progression.	Approximately 7months/patient- screening period is not included. Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent, date of disease progression or whichever occurs first
2a-Incidence, type and severity of TEAEs	Summary of the treatment-emergent Adverse events experienced during treatment. Adverse events are assessed with Common Terminology Criteria for Adverse Events (CTCAE) 5.0. TEAEs are defined as any medical occurrence reported or observed after the start of dosing with investigational product until completion of the last study related procedure (including follow-up for safety assessments)	From start of dosing until 30 days after the last dose of ACT001
2a-Concentration of ACT001 in resected tumor biopsy tissue.		Tissue at Surgical Resection only.

Collaborators and Investigators

• Sponsor: Accendatech USA Inc.
• Collaborators: Avance Clinical Pty Ltd.; C3 Research Associates
• Investigators: Study Director: Doug Cai, MD, Accendatech USA Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 22, 2021
• Primary Completion (ANTICIPATED): November 1, 2022
• Study Completion (ANTICIPATED): November 1, 2023

Study Registration Dates

• First Submitted: August 12, 2021
• First Submitted That Met QC Criteria: September 13, 2021
• First Posted (ACTUAL): September 23, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 19, 2021
• Last Update Submitted That Met QC Criteria: November 12, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: GBM; Brain; Neoplasm; Blastoma
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Disease Attributes; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma; Recurrence; Antineoplastic Agents; Antineoplastic Agents, Immunological; Pembrolizumab
• Other Study ID Numbers: ACT001-US-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No